JP6637885B2 - マイクロバイオームの特性解明、モニタリング、および処置のための方法およびシステム - Google Patents

マイクロバイオームの特性解明、モニタリング、および処置のための方法およびシステム Download PDF

Info

Publication number
JP6637885B2
JP6637885B2 JP2016529820A JP2016529820A JP6637885B2 JP 6637885 B2 JP6637885 B2 JP 6637885B2 JP 2016529820 A JP2016529820 A JP 2016529820A JP 2016529820 A JP2016529820 A JP 2016529820A JP 6637885 B2 JP6637885 B2 JP 6637885B2
Authority
JP
Japan
Prior art keywords
bacteroides
microorganisms
microbiome
less
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016529820A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016525355A5 (enExample
JP2016525355A (ja
Inventor
カットクリフ，コリーン
イード，ジョン・エス
ブラード，ジェームズ・エイチ
Original Assignee
ペンデュラム セラピューティクス， インコーポレイテッド
ペンデュラム セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ペンデュラム セラピューティクス， インコーポレイテッド, ペンデュラム セラピューティクス， インコーポレイテッド filed Critical ペンデュラム セラピューティクス， インコーポレイテッド
Publication of JP2016525355A publication Critical patent/JP2016525355A/ja
Publication of JP2016525355A5 publication Critical patent/JP2016525355A5/ja
Application granted granted Critical
Publication of JP6637885B2 publication Critical patent/JP6637885B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00659—Two-dimensional arrays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016529820A 2013-07-21 2014-07-21 マイクロバイオームの特性解明、モニタリング、および処置のための方法およびシステム Active JP6637885B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361856711P 2013-07-21 2013-07-21
US61/856,711 2013-07-21
PCT/US2014/047491 WO2015013214A2 (en) 2013-07-21 2014-07-21 Methods and systems for microbiome characterization, monitoring and treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019231106A Division JP2020072680A (ja) 2013-07-21 2019-12-23 マイクロバイオームの特性解明、モニタリング、および処置のための方法およびシステム

Publications (3)

Publication Number Publication Date
JP2016525355A JP2016525355A (ja) 2016-08-25
JP2016525355A5 JP2016525355A5 (enExample) 2017-08-31
JP6637885B2 true JP6637885B2 (ja) 2020-01-29

Family

ID=52393950

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016529820A Active JP6637885B2 (ja) 2013-07-21 2014-07-21 マイクロバイオームの特性解明、モニタリング、および処置のための方法およびシステム
JP2019231106A Pending JP2020072680A (ja) 2013-07-21 2019-12-23 マイクロバイオームの特性解明、モニタリング、および処置のための方法およびシステム

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019231106A Pending JP2020072680A (ja) 2013-07-21 2019-12-23 マイクロバイオームの特性解明、モニタリング、および処置のための方法およびシステム

Country Status (5)

Country Link
US (2) US10633714B2 (enExample)
JP (2) JP6637885B2 (enExample)
CN (1) CN105407728A (enExample)
GB (1) GB2535034A (enExample)
WO (1) WO2015013214A2 (enExample)

Families Citing this family (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US10940169B2 (en) 2015-11-30 2021-03-09 Joseph E. Kovarik Method for reducing the likelihood of developing cancer in an individual human being
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
WO2013139861A1 (en) 2012-03-20 2013-09-26 Luc Montagnier Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
EP3011046A4 (en) 2013-06-18 2017-03-01 Prodermiq, Inc. Customized skin care products and personal care products based on the analysis of skin flora
US10633714B2 (en) 2013-07-21 2020-04-28 Pendulum Therapeutics, Inc. Methods and systems for microbiome characterization, monitoring and treatment
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11026982B2 (en) 2015-11-30 2021-06-08 Joseph E. Kovarik Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being
US11642382B2 (en) 2013-12-20 2023-05-09 Seed Health, Inc. Method for treating an individual suffering from bladder cancer
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11672835B2 (en) 2013-12-20 2023-06-13 Seed Health, Inc. Method for treating individuals having cancer and who are receiving cancer immunotherapy
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11213552B2 (en) 2015-11-30 2022-01-04 Joseph E. Kovarik Method for treating an individual suffering from a chronic infectious disease and cancer
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11529379B2 (en) 2013-12-20 2022-12-20 Seed Health, Inc. Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
US10361003B2 (en) 2014-04-28 2019-07-23 Yeda Research And Development Co. Ltd. Method and apparatus for predicting response to food
US10410749B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
US10789334B2 (en) 2014-10-21 2020-09-29 Psomagen, Inc. Method and system for microbial pharmacogenomics
US10169541B2 (en) 2014-10-21 2019-01-01 uBiome, Inc. Method and systems for characterizing skin related conditions
US10395777B2 (en) 2014-10-21 2019-08-27 uBiome, Inc. Method and system for characterizing microorganism-associated sleep-related conditions
US10409955B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for locomotor system conditions
US9710606B2 (en) 2014-10-21 2017-07-18 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US10073952B2 (en) 2014-10-21 2018-09-11 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US10388407B2 (en) 2014-10-21 2019-08-20 uBiome, Inc. Method and system for characterizing a headache-related condition
US10777320B2 (en) 2014-10-21 2020-09-15 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions
US10265009B2 (en) 2014-10-21 2019-04-23 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features
US9760676B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US10793907B2 (en) 2014-10-21 2020-10-06 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US10325685B2 (en) 2014-10-21 2019-06-18 uBiome, Inc. Method and system for characterizing diet-related conditions
US10311973B2 (en) 2014-10-21 2019-06-04 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US9754080B2 (en) 2014-10-21 2017-09-05 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cardiovascular disease conditions
US10381112B2 (en) 2014-10-21 2019-08-13 uBiome, Inc. Method and system for characterizing allergy-related conditions associated with microorganisms
US10366793B2 (en) 2014-10-21 2019-07-30 uBiome, Inc. Method and system for characterizing microorganism-related conditions
US10357157B2 (en) 2014-10-21 2019-07-23 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features
US9703929B2 (en) 2014-10-21 2017-07-11 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics
US11783914B2 (en) 2014-10-21 2023-10-10 Psomagen, Inc. Method and system for panel characterizations
US9758839B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome functional features
US10346592B2 (en) 2014-10-21 2019-07-09 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
EP4529950A3 (en) 2014-10-31 2025-08-20 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment
ES2794125T3 (es) * 2014-12-08 2020-11-17 Gi Biome Composición farmacéutica para prevenir o tratar enfermedades metabólicas, que comprende Bacteroides acidifaciens como principio activo
PL3193901T3 (pl) 2014-12-23 2018-10-31 4D Pharma Research Limited Polipeptyd pyrynowy i immunomodulacja
CN113862175A (zh) 2014-12-23 2021-12-31 4D制药研究有限公司 免疫调控
CN107708715B (zh) * 2015-04-13 2022-06-03 普梭梅根公司 用于微生物组功能特征相关的状况的微生物组来源的诊断和治疗的方法及系统
WO2016168350A1 (en) * 2015-04-13 2016-10-20 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
AU2016250096A1 (en) * 2015-04-13 2017-11-09 Psomagen, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features
WO2016168352A1 (en) * 2015-04-13 2016-10-20 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features
CN107849609B (zh) * 2015-04-13 2022-01-25 普梭梅根公司 用于心理健康相关状况的微生物组来源的诊断和治疗的方法及系统
AU2016248063A1 (en) * 2015-04-13 2017-11-09 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US10246753B2 (en) 2015-04-13 2019-04-02 uBiome, Inc. Method and system for characterizing mouth-associated conditions
EP3283648A4 (en) * 2015-04-13 2019-03-20 Ubiome Inc. METHOD AND SYSTEM FOR MICROBIBLE-DERIVED DIAGNOSTICS AND THERAPEUTICS FOR NEUROLOGICAL HEALTH PROBLEMS
WO2016168355A1 (en) * 2015-04-14 2016-10-20 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for locomotor system conditions
CN107710205A (zh) * 2015-04-14 2018-02-16 优比欧迈公司 用于心血管疾病状况的微生物组来源的表征、诊断和治疗的方法及系统
EP3283087A4 (en) * 2015-04-14 2019-03-13 Ubiome Inc. METHOD AND SYSTEM FOR MICROBIOMEDIVED DIAGNOSTICS AND THERAPEUTICS FOR DISEASES OF THE ENDOCRINE SYSTEM
US10788452B2 (en) 2015-04-21 2020-09-29 General Automation Lab Technologies Inc. High resolution systems, kits, apparatus, and methods for bacterial community relationship determination and other high throughput microbiology applications
MD3206700T2 (ro) 2015-06-15 2019-12-31 4D Pharma Res Ltd Compoziții conținând tulpini bacteriene
RS59446B1 (sr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Blautia stercosis i wexlerae za upotrebu u lečenju inflamatornih i autoimunskih bolesti
PE20180267A1 (es) 2015-06-15 2018-02-06 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
US11001900B2 (en) 2015-06-30 2021-05-11 Psomagen, Inc. Method and system for characterization for female reproductive system-related conditions associated with microorganisms
JP6046849B1 (ja) * 2015-07-21 2016-12-21 ＴＡＫ−Ｃｉｒｃｕｌａｔｏｒ株式会社 身体状態の評価方法、情報の提示方法、および身体状態を改善又は予防する物質のスクリーニング方法
US20190087536A1 (en) * 2015-09-09 2019-03-21 uBiome. Inc Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with thyroid health issues
CA3005987A1 (en) * 2015-09-09 2017-03-16 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with gastrointestinal health
EP3347496A4 (en) * 2015-09-09 2019-08-07 Ubiome Inc. METHOD AND SYSTEM FOR DIAGNOSES DERIVED FROM MICROBIOMA AND THERAPEUTIC TREATMENTS FOR BUCCO-DENTAL HEALTH
WO2017048664A1 (en) 2015-09-15 2017-03-23 Neogen Corporation Methods of detecting listeria from an environmental sample
EP3350761B1 (en) 2015-09-17 2023-12-20 Prodermiq, Inc. Predicting skin age based on the analysis of skin flora and lifestyle data
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
WO2017085520A1 (en) 2015-11-20 2017-05-26 4D Pharma Research Limited Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
CN108472506B (zh) * 2015-12-09 2022-03-29 普梭梅根公司 用于表征艰难梭菌相关病症的方法和系统
WO2017109059A1 (en) * 2015-12-22 2017-06-29 Vib Vzw Microbial marker in inflammatory arthritis diseases
WO2017141169A1 (en) * 2016-02-16 2017-08-24 Tata Consultancy Services Limited Method and system for early risk assessment of preterm delivery outcome
JP6441536B2 (ja) 2016-03-04 2018-12-19 フォーディー ファーマ ピーエルシー４Ｄ Ｐｈａｒｍａ Ｐｌｃ 細菌株を含む組成物
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
CN108699586B (zh) * 2016-03-07 2022-09-20 普梭梅根公司 用于表征与口相关病症的方法和系统
US10894990B2 (en) 2016-05-17 2021-01-19 Shoreline Biome, Llc High throughput method for identification and sequencing of unknown microbial and eukaryotic genomes from complex mixtures
JP7655693B2 (ja) 2016-05-23 2025-04-02 カリフォルニア インスティチュート オブ テクノロジー 神経変性障害を治療するための腸内微生物叢の制御
CN107541544A (zh) * 2016-06-27 2018-01-05 卡尤迪生物科技（北京）有限公司 用于确定微生物分布谱的方法、系统、试剂盒、用途和组合物
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
WO2018013865A1 (en) * 2016-07-13 2018-01-18 uBiome, Inc. Method and system for microbial pharmacogenomics
JP6862464B2 (ja) * 2016-09-06 2021-04-21 ビージーアイ シェンチェン フィーカリバクテリウム・ロンガム（Ｆａｅｃａｌｉｂａｃｔｅｒｉｕｍ ｌｏｎｇｕｍ）およびその使用
US11959125B2 (en) 2016-09-15 2024-04-16 Sun Genomics, Inc. Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample
SG11201901726QA (en) * 2016-09-16 2019-03-28 Ubiome Inc Method and system for panel characterizations
WO2018064226A1 (en) * 2016-09-27 2018-04-05 uBiome, Inc. Method and system for crispr-based library preparation and sequencing
AU2017335897A1 (en) * 2016-09-28 2019-04-04 General Automation Lab Technologies, Inc. High resolution systems, kits, apparatus, and methods for bacterial community relationship determination and other high throughput microbiology applications
US11015154B2 (en) 2016-11-09 2021-05-25 The Regents Of The University Of California Methods for identifying interactions amongst microorganisms
JP6955860B2 (ja) * 2016-11-30 2021-10-27 花王株式会社 デリケートエリアのかぶれ判定方法
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
WO2018112437A1 (en) * 2016-12-15 2018-06-21 uBiome, Inc. Method and system for characterizing allergy-related conditions associated with microorganisms
WO2018112459A1 (en) * 2016-12-16 2018-06-21 uBiome, Inc. Method and system for characterizing microorganism-related conditions
CN110546278B (zh) * 2017-02-24 2024-06-28 Md保健株式会社 通过细菌宏基因组分析来诊断慢性阻塞性呼吸道疾病的方法
WO2018165621A1 (en) 2017-03-10 2018-09-13 Prodermiq, Inc. Customized skin care products and personal care products based on the analysis of skin flora
CN107034279A (zh) * 2017-05-05 2017-08-11 中山大学 结核病微生物标志物在制备诊断结核病的试剂中的应用
US11147792B2 (en) 2017-05-15 2021-10-19 Axial Therapeutics, Inc. Inhibitors of microbially induced amyloid
HUE054164T2 (hu) 2017-05-22 2021-08-30 4D Pharma Res Ltd Baktériumtörzseket tartalmazó készítmények
WO2018215782A1 (en) 2017-05-24 2018-11-29 4D Pharma Research Limited Compositions comprising bacterial strain
CN109082479B (zh) * 2017-06-14 2022-04-19 深圳华大生命科学研究院 从样本中鉴定微生物物种的方法和装置
SMT202000695T1 (it) 2017-06-14 2021-01-05 4D Pharma Res Limited Composizioni comprendenti ceppi batterici
MA49010B1 (fr) 2017-06-14 2020-11-30 4D Pharma Res Ltd Compositions comprenant une souche bactérienne du genre megasphaera et leurs utilisations
LT3600363T (lt) 2017-06-14 2021-02-10 4D Pharma Research Limited Kompozicijos, apimančios bakterijų kamienus
JP2020532979A (ja) * 2017-08-28 2020-11-19 プソマーゲン， インコーポレイテッドＰｓｏｍａｇｅｎ， Ｉｎｃ． 微生物に関連する女性生殖器系関連状態の特徴解析のための方法及びシステム
JP7079320B2 (ja) * 2017-08-29 2022-06-01 ビージーアイ シェンチェン 脂質代謝関連疾患を予防及び／又は治療するための組成物の調製におけるＡｌｉｓｔｉｐｅｓ ｓｈａｈｉｉの適用
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
KR101831416B1 (ko) * 2017-09-04 2018-02-22 이화여자대학교 산학협력단 시료 내 미생물 군집의 변화를 이용한 조산 위험성 예측
JP2021502124A (ja) * 2017-11-06 2021-01-28 プソマーゲン， インコーポレイテッドＰｓｏｍａｇｅｎ， Ｉｎｃ． 微生物関連特徴解析プロセスのための対照プロセス
WO2019094702A1 (en) 2017-11-10 2019-05-16 Cocoon Biotech Inc. Ocular applications of silk-based products
WO2019118984A2 (en) 2017-12-15 2019-06-20 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
EP3728645A4 (en) * 2017-12-22 2021-09-08 Gutfeeling Labs AB HEALTH STATE ANALYSIS PROCESS
AU2019205296B2 (en) * 2018-01-05 2021-12-23 Nubiyota Llc Compositions comprising co-selected microbiota and methods for use thereof
WO2019151825A1 (ko) * 2018-02-02 2019-08-08 주식회사 엠디헬스케어 비피도박테리움 속 세균 유래 나노소포 및 이의 용도
KR102194286B1 (ko) 2018-02-08 2020-12-22 주식회사 엠디헬스케어 락토코커스 속 세균 유래 나노소포 및 이의 용도
WO2019156449A1 (ko) * 2018-02-08 2019-08-15 주식회사 엠디헬스케어 락토코커스 속 세균 유래 나노소포 및 이의 용도
KR102118989B1 (ko) 2018-03-05 2020-06-05 주식회사 엠디헬스케어 엔히드로박터 세균 유래 나노소포 및 이의 용도
US11525164B2 (en) 2018-03-27 2022-12-13 The Trustees Of Columbia University In The City Of New York Spatial metagenomic characterization of microbial biogeography
KR101872457B1 (ko) * 2018-04-20 2018-06-28 이화여자대학교 산학협력단 혈액 내 미생물 군집의 변화를 이용한 조산 위험성의 예측
EP4512910A3 (en) 2018-06-29 2025-06-11 Osaka University Method of detecting conjunctival disease using ocular surface tissue, and aging biomarker
CA3106315A1 (en) 2018-07-19 2020-01-23 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
WO2020051379A1 (en) 2018-09-05 2020-03-12 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases
US20210318307A1 (en) * 2018-09-19 2021-10-14 Baylor College Of Medicine Precision diagnosis of clostridioides difficile infection using a systems-based biomarkers
CN109273046B (zh) * 2018-10-19 2022-04-22 江苏东南证据科学研究院有限公司 一种基于概率统计模型的生物学全同胞鉴定方法
EP3870550A4 (en) * 2018-10-26 2022-11-02 Sun Genomics Inc. UNIVERSAL PROCEDURE FOR THE EXTRACTION OF NUCLEIC ACID MOLECULES FROM A DIVERSE POPULATION OF MICROBES
WO2020088596A1 (en) * 2018-10-31 2020-05-07 Coyote Diagnostics Lab (Beijing) Co., Ltd. Methods, systems and kits for predicting premature birth condition
WO2020093040A1 (en) * 2018-11-02 2020-05-07 The Regents Of The University Of California Methods to diagnose and treat cancer using non-human nucleic acids
WO2020213732A1 (ja) * 2019-04-18 2020-10-22 株式会社サイキンソー 過敏性腸症候群の検査方法
US11884958B2 (en) 2019-04-30 2024-01-30 Mayo Foundation For Medical Education And Research Assessing and treating functional gastrointestinal disorders
CN110541026A (zh) * 2019-08-17 2019-12-06 昆明医科大学第一附属医院 一种检测溃疡性结肠炎的生物标志物及应用
CN114555834A (zh) * 2019-09-02 2022-05-27 迈奥诊断公司 用于改善全身健康的皮肤微生物组监测
MX2022004004A (es) * 2019-10-04 2022-06-16 Vytelle Llc Composiciones, metodos y kits para la seleccion de donantes y receptores para la fecundacion in vitro.
CN110903999B (zh) * 2019-10-23 2021-11-23 上海市第十人民医院 一株人类肠道分离的具核梭杆菌动物亚种菌株及其应用
EP3839072A1 (en) * 2019-12-17 2021-06-23 Luxia Scientific Bacterial combinations predictive of the activity of multiple sclerosis
US20230218680A1 (en) * 2020-01-29 2023-07-13 Tata Consultancy Services Limited Method and composition for microbiome based amelioration of skin associated autoimmune inflammatory diseases
US20210265029A1 (en) * 2020-02-21 2021-08-26 Zoe Global Limited Generating microbiome fingerprints, dietary fingerprints, and microbiome ancestry
WO2021202584A1 (en) * 2020-03-30 2021-10-07 The Regents Of The University Of California Systems and methods for gut microbiome precision medicine
US20210319848A1 (en) * 2020-04-08 2021-10-14 Fred Hutchinson Cancer Research Center Systems and methods for identifying associations between microbial strains and phenotypic features
CN114078568B (zh) * 2020-09-14 2022-07-05 青岛欧易生物科技有限公司 基于iib型限制性内切酶特征的宏基因组测序数据处理系统及处理方法
US11139063B1 (en) 2020-12-29 2021-10-05 Kpn Innovations, Llc. Systems and methods for generating a microbiome balance plan for prevention of bacterial infection
US12322493B2 (en) * 2020-12-29 2025-06-03 Kpn Innovations, Llc. Systems and methods for generating a lifestyle-based disease prevention plan
US12322491B2 (en) 2021-03-01 2025-06-03 Kpn Innovations, Llc. System and method for generating a geographically linked nourishment program
KR102304402B1 (ko) * 2021-03-26 2021-09-24 주식회사 에이치이엠파마 머신러닝 모델을 이용하여 비만 여부를 판별하는 방법 및 진단 장치
CN112961807B (zh) * 2021-03-30 2023-01-20 中国科学院成都生物研究所 一种微生物组合物及在促进青稞种子发芽和生长上的应用
JP7643909B2 (ja) * 2021-03-30 2025-03-11 株式会社日立ハイテク 分析装置、分析システム、分析方法、およびプログラム
WO2022211796A1 (en) * 2021-03-31 2022-10-06 Neogen Corporation Detecting salmonella from an environmental sample
WO2023092150A1 (en) 2021-11-22 2023-05-25 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
CN114807392B (zh) * 2021-12-08 2025-02-25 杭州拓宏生物科技有限公司 精神分裂症标志微生物及其应用
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities
CN114373505B (zh) * 2021-12-29 2022-11-01 浙江大学 一种基于肠道微生物早期预测奶牛产后亚临床酮病的系统
KR102760485B1 (ko) * 2022-01-03 2025-02-03 연세대학교 산학협력단 자궁내막증 진단을 위한 정보 제공 방법
WO2023164493A1 (en) * 2022-02-23 2023-08-31 Jona, Inc. System and method for using the microbiome to improve healthcare
WO2023220080A1 (en) * 2022-05-11 2023-11-16 J. Craig Venter Institute, Inc. Methods and systems for determining dental caries
US12512224B2 (en) * 2022-12-14 2025-12-30 Immunobiome Inc. Method of discovering disease-relevant microbial consortia using machine-learning model
CN115980346B (zh) * 2022-12-26 2025-07-15 云南大学 一种基于金属有机框架材料构建比色免疫传感器检测新型冠状病毒的方法
EP4689190A1 (en) * 2023-03-28 2026-02-11 ZOE Limited Directional alteration of an individual's microbiome
CN117965384B (zh) * 2024-02-08 2025-11-21 北京林业大学 一种用于液化降解餐厨垃圾的降解菌及包含其的菌剂和应用
WO2025189001A2 (en) * 2024-03-06 2025-09-12 University Of Florida Research Foundation, Incorporated Methods of reducing occurrence of neurodevelopmental disorders
CN118813503B (zh) * 2024-09-19 2025-05-27 中国海洋大学 一种索氏鲸杆菌、索氏鲸杆菌后生元及其制备方法和应用
CN119614730B (zh) * 2025-02-17 2025-05-13 美益添生物医药(武汉)有限公司 一种与帕金森综合征相关的肠道菌群标志物及其应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4789734A (en) 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
NL8720442A (nl) 1986-08-18 1989-04-03 Clinical Technologies Ass Afgeefsystemen voor farmacologische agentia.
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
JPH08505625A (ja) 1993-01-11 1996-06-18 ダナ−ファーバー キャンサー インスティチュート 細胞毒性ｔリンパ球応答の誘導
US5531989A (en) 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
US6241983B1 (en) 1994-10-28 2001-06-05 Metagenics, Inc. Bacteria-and fiber-containing composition for human gastrointestinal health
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
US7056661B2 (en) 1999-05-19 2006-06-06 Cornell Research Foundation, Inc. Method for sequencing nucleic acid molecules
JP4580542B2 (ja) 2000-05-17 2010-11-17 株式會社バイオニア 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
WO2002085415A1 (en) 2001-04-17 2002-10-31 Biomatrix, Inc Non-digestible sugar-coated products and process
US7101565B2 (en) 2002-02-05 2006-09-05 Corpak Medsystems, Inc. Probiotic/prebiotic composition and delivery method
ITBO20020564A1 (it) 2002-09-06 2004-03-07 Alfa Wassermann Spa Bifidobatteri e preparazioni che li contengono.
EP1600060A1 (en) 2004-05-25 2005-11-30 Cognis IP Management GmbH Oral and/or topical compositions comprising prebiotics and fatty acid
US20060115465A1 (en) 2004-10-29 2006-06-01 Macfarlane George Treatment of gastrointestinal disorders
JP5565991B2 (ja) 2004-12-15 2014-08-06 株式会社島津製作所 微生物菌種推定システム及び方法
CN101095698B (zh) 2006-06-26 2010-12-01 青岛东海药业有限公司 酪酸梭菌防治便臭毒素引起的相关症状和疾病的用途
WO2008076696A2 (en) 2006-12-18 2008-06-26 Washington University In St. Louis The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
CN101688171B (zh) 2007-03-28 2013-03-27 营养健康有限公司 益生双歧杆菌菌株
EP2134835B1 (en) 2007-03-28 2014-10-15 Alimentary Health Limited Probiotic bifidobacterium strains
EP1985712A1 (en) * 2007-04-17 2008-10-29 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Microbial population analysis
US8478544B2 (en) * 2007-11-21 2013-07-02 Cosmosid Inc. Direct identification and measurement of relative populations of microorganisms with direct DNA sequencing and probabilistic methods
EP2110028A1 (en) 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum and hippocampal BDNF expression
EP2808024B1 (en) 2009-06-19 2019-04-24 DuPont Nutrition Biosciences ApS Bifidobacteria for treating congestive heart failure
US9848760B2 (en) * 2009-06-29 2017-12-26 Gearbox, Llc Devices for continual monitoring and introduction of gastrointestinal microbes
EP2459203B1 (en) 2009-07-30 2018-10-31 DuPont Nutrition Biosciences ApS Lactic acid bacteria and bifidobacteria for treating endotoxemia
DK2289527T3 (en) 2009-08-25 2018-04-23 Nestec Sa BIFIDOBACTERIUM LONGUM AND FUNCTIONAL GI DISEASES
CN101792807B (zh) * 2010-03-25 2012-12-05 复旦大学 一种微生物群落结构的分析方法
FI20105478A0 (fi) 2010-04-30 2010-04-30 Valtion Teknillinen Menetelmä tyypin 1 diabeteksen diagnosoimiseksi ja menetelmiä ja koostumuksia tyypin 1 diabeteksen puhkeamisen estämiseksi
US8951512B2 (en) 2010-05-04 2015-02-10 New York University Methods for treating bone disorders by characterizing and restoring mammalian bacterial microbiota
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
RU2613322C2 (ru) 2011-08-30 2017-03-15 Академис Медис Сентрум Способ профилактики и/или лечения инсулинорезистентности
US20130121968A1 (en) * 2011-10-03 2013-05-16 Atossa Genetics, Inc. Methods of combining metagenome and the metatranscriptome in multiplex profiles
FI20116008A0 (fi) 2011-10-12 2011-10-12 Maeyrae Maekinen Annika Viskeraalisen rasvan estäminen ja diagnostisointi
WO2013130773A2 (en) 2012-02-29 2013-09-06 Ethicon Endo-Surgery, Inc. Compositions of microbiota and methods related thereto
EP3692999A1 (en) 2012-03-17 2020-08-12 The Regents of the University of California Fast diagnosis and personalized treatments for acne
JP6286434B2 (ja) 2012-09-20 2018-02-28 プロセラ インコーポレイテッド 肥満および肥満関連疾患の治療のためのプロバイオティクス組成物および方法
WO2014075745A1 (en) 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
DK3628161T3 (da) 2012-11-23 2023-05-30 Seres Therapeutics Inc Synergistiske bakterielle sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
WO2014121304A1 (en) 2013-02-04 2014-08-07 Seres Health, Inc. Compositions and methods
AU2014212004B2 (en) 2013-02-04 2018-09-20 Société des Produits Nestlé S.A. Compositions for treating or preventing or reducing the severity of clostridium difficile related diseases
AU2014226633A1 (en) 2013-03-05 2015-09-03 Academisch Ziekenhuis Groningen Use of Faecali bacterium prausnitzii HTF-F (DSM 26943) to suppress inflammation.
WO2014153194A2 (en) 2013-03-14 2014-09-25 Seres Health, Inc. Methods for pathogen detection and enrichment from materials and compositions
EP2967077A4 (en) 2013-03-15 2016-09-14 Seres Therapeutics Inc NETWORK-BASED MICROBIAL COMPOSITIONS AND METHOD
US10633714B2 (en) 2013-07-21 2020-04-28 Pendulum Therapeutics, Inc. Methods and systems for microbiome characterization, monitoring and treatment
WO2015051323A1 (en) 2013-10-03 2015-04-09 Trustees Of The University Of Pennsylvania Compositions comprising a defined microbiome and methods of use thereof
GB201319531D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition & methods of screening
GB201319539D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition & methods of screening
GB201319525D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition
GB201319538D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition
GB201319540D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition
KR102611070B1 (ko) 2013-11-25 2023-12-07 세레스 테라퓨틱스, 인코포레이티드 상승적 박테리아 조성물 및 그것의 생산 방법 및 용도
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
US20150246081A1 (en) 2014-03-03 2015-09-03 Shayne Kenneth Morris Probiotics with methods for growth and use separately and in combination
FI127483B (en) 2014-06-11 2018-07-13 Gut Guide Oy Microbial marker for celiac disease and related product

Also Published As

Publication number Publication date
GB2535034A (en) 2016-08-10
WO2015013214A2 (en) 2015-01-29
US20200277658A1 (en) 2020-09-03
GB201602937D0 (en) 2016-04-06
JP2020072680A (ja) 2020-05-14
CN105407728A (zh) 2016-03-16
US10633714B2 (en) 2020-04-28
JP2016525355A (ja) 2016-08-25
WO2015013214A3 (en) 2015-03-26
US20150259728A1 (en) 2015-09-17

Similar Documents

Publication Publication Date Title
JP6637885B2 (ja) マイクロバイオームの特性解明、モニタリング、および処置のための方法およびシステム
McCallum et al. The gut microbiota and its biogeography
Zhou et al. Dynamic development of fecal microbiome during the progression of diabetes mellitus in Zucker diabetic fatty rats
Lebreton et al. Tracing the enterococci from Paleozoic origins to the hospital
Baumgart et al. Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum
Klymiuk et al. The human gastric microbiome is predicated upon infection with Helicobacter pylori
Angelakis et al. A metagenomic investigation of the duodenal microbiota reveals links with obesity
Hansen et al. Microbiota ofDe-NovoPediatric IBD: IncreasedFaecalibacterium Prausnitziiand Reduced Bacterial Diversity in Crohn's But Not in Ulcerative Colitis
JP6868562B2 (ja) 障害の微生物的処置および診断に関する方法および組成物
Mshvildadze et al. Intestinal microbiota development in the premature neonate: establishment of a lasting commensal relationship?
Guarino et al. Retraction: Composition and roles of intestinal microbiota in children
CN101815791A (zh) 微生物种群分析
Wu-Woods et al. Microbial-enrichment method enables high-throughput metagenomic characterization from host-rich samples
Loughman et al. Attenuation of human neutrophil migration and function by uropathogenic bacteria
Ding et al. Airway environment drives the selection of quorum sensing mutants and promote Staphylococcus aureus chronic lifestyle
Chmiel et al. New perspectives on an old grouping: The genomic and phenotypic variability of Oxalobacter formigenes and the implications for calcium oxalate stone prevention
Ignys et al. Methods of analysis of gut microorganism–actual state of knowledge
Mathuria et al. Multi-omics in gut microbiome
Treerat et al. Oral microbiome diversity: The curious case of Corynebacterium sp. isolation
Bhatt et al. A rare urinary tract infection of multidrug-resistant Chryseobacterium urinae sp. nov. isolated from a diabetic, non-catheterized patient
Rajilic-Stojanovic Diversity of the human gastrointestinal microbiota: novel perspectives from high throughput analyses
Nalage et al. First Three Days of Life
Higgins Investigating the Predatory Capability of Bdellovibrio bacteriovorus towards Colorectal Cancer Oncomicrobes in vitro
CN111108199B (zh) 用于动脉粥样硬化性心血管疾病的生物标志物
Yang et al. Unveiling the gut-heart potential connection: microbiota’s role in kawasaki disease and coronary artery lesions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170721

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170721

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20170825

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20171017

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180607

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190627

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191223

R150 Certificate of patent or registration of utility model

Ref document number: 6637885

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250